Plain-English translation of NCT06597695 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Depression research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage research study testing ketamine-assisted group therapy for Spanish-speaking adults living with depression. Ketamine is a medication that has shown promise in helping people with depression, especially when combined with therapy and group support. Researchers want to learn whether this combined approach is safe, feasible to deliver to groups, and helpful for reducing depression symptoms.
Depression affects many people, and some individuals don't respond well to standard antidepressant medications. This medication has emerging evidence as a potential option, but researchers want to understand whether delivering it alongside group therapy—which provides both support and practical coping tools—could be an effective approach, especially for Spanish-speaking communities.
You likely qualify if…
You likely don't qualify if…
This is a small pilot study enrolling about 10 people. You would participate in group therapy sessions where ketamine is administered as part of the treatment. The exact schedule of visits and duration would be determined by the research team, but you would be working with a clinician and a group of other participants who are also being treated for depression. The goal is to assess whether this combination approach is safe and helpful.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Juliana Zambrano, MD, MPH
Enrollment target
~10 participants
Started
July 2025
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 64 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Juliana Zambrano, MD
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.